Promore Pharma: Raising capital at a deep discount

Research Note

2019-10-07

08:55

The announcement of a rights issue (guaranteed up to 80 percent) was no big surprise. The surprise was instead the insufficient size of capital being raised (~SEK 75m), the very deep discount of the issue price (~70% compared to the previous closing), and high transaction costs (16-20% depending on subscription amount). Taking all this into account, we lower our base case value.

KP

Klas Palin

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.